枸橼酸铋与多种抗菌剂对幽门弯曲菌（幽门螺杆菌）的体外协同活性。
In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).
作者信息
Van Caekenberghe D L, Breyssens J
机构信息
Department of Medical Microbiology, Military Hospital, Brussels, Belgium.
出版信息
Antimicrob Agents Chemother. 1987 Sep;31(9):1429-30. doi: 10.1128/AAC.31.9.1429.
Abstract
The in vitro interactions between bismuth subcitrate and a variety of antimicrobial agents against 12 Campylobacter pyloridis (C. pylori) isolates were studied by the agar dilution checkerboard technique. The combination of bismuth subcitrate with the older quinolone, oxolinic acid, produced synergistic activity against all strains. This observation, however, could not be extended to the (aryl) fluoroquinolones, norfloxacin, ofloxacin, and difloxacin, since synergy was rare or absent when bismuth subcitrate was combined with these antibiotics. Among the other antimicrobial agents tested, rifampin and the beta-lactams frequently showed showed MICs for C. pyloridis similar to those of bismuth subcitrate.
摘要
采用琼脂稀释棋盘法研究了枸橼酸铋与多种抗菌剂对12株幽门弯曲菌（幽门螺杆菌）的体外相互作用。枸橼酸铋与较老的喹诺酮类药物奥索利酸联合使用时，对所有菌株均产生协同活性。然而，这一观察结果不能推广到（芳基）氟喹诺酮类药物诺氟沙星、氧氟沙星和双氟沙星，因为枸橼酸铋与这些抗生素联合使用时，协同作用很少或不存在。在测试的其他抗菌剂中，利福平及β-内酰胺类药物对幽门螺杆菌的最低抑菌浓度（MIC）通常与枸橼酸铋相似。
相似文献
1
In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).枸橼酸铋与多种抗菌剂对幽门弯曲菌（幽门螺杆菌）的体外协同活性。
Antimicrob Agents Chemother. 1987 Sep;31(9):1429-30. doi: 10.1128/AAC.31.9.1429.
2
In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.幽门弯曲菌对西咪替丁、硫糖铝、铋及十六种抗生素的体外敏感性
Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):147-9. doi: 10.1111/j.1699-0463.1987.tb03103.x.
3
Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.幽门螺杆菌临床分离株对24种抗菌和抗溃疡药物的敏感性。
Eur J Epidemiol. 1988 Jun;4(2):154-7. doi: 10.1007/BF00144743.
4
Synergism between clindamycin and colloidal bismuth subcitrate against Helicobacter (Campylobacter) pylori in vitro.
Zentralbl Bakteriol. 1990 Nov;274(2):246-9. doi: 10.1016/s0934-8840(11)80107-6.
5
The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori.
Zentralbl Bakteriol. 1989 Sep;271(3):304-10. doi: 10.1016/s0934-8840(89)80028-3.
6
Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.曲古霉素与枸橼酸铋胶体联合应用对幽门螺杆菌的体外抗菌活性
Infection. 1991 May-Jun;19(3):138-9. doi: 10.1007/BF01643232.
7
Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.硝酸铋和枸橼酸铋胶体的溶解度、吸收及抗幽门螺杆菌活性：体外数据无法预测体内疗效。
Helicobacter. 2000 Sep;5(3):176-82. doi: 10.1046/j.1523-5378.2000.00028.x.
8
Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.幽门螺杆菌对诺氟沙星及其他药物的敏感性比较。
Antimicrob Agents Chemother. 1987 Jun;31(6):949-50. doi: 10.1128/AAC.31.6.949.
9
In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.新型口服β-内酰胺类药物和大环内酯类药物对幽门螺杆菌的体外活性
Antimicrob Agents Chemother. 1989 Sep;33(9):1650-1. doi: 10.1128/AAC.33.9.1650.
10
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.幽门弯曲菌临床分离株对11种抗菌药物的敏感性
Antimicrob Agents Chemother. 1985 Dec;28(6):837-8. doi: 10.1128/AAC.28.6.837.
引用本文的文献
1
Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones.优化策略旨在提高喹诺酮类药物根除疗法的疗效。
Molecules. 2020 Nov 2;25(21):5084. doi: 10.3390/molecules25215084.
2
Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant .协同疗法作为治疗抗生素耐药性的一种有前景的选择。
Antibiotics (Basel). 2020 Sep 30;9(10):658. doi: 10.3390/antibiotics9100658.
3
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.谁将赢得这场战争？幽门螺杆菌抗生素耐药性的分子机制
Curr Drug ther. 2008 Sep 1;3(3):190-203. doi: 10.2174/157488508785747899.
4
The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation.铋对幽门螺杆菌的作用类似于细胞内铁剥夺，但并非由细胞内铁剥夺引起。
Antimicrob Agents Chemother. 2004 Jun;48(6):1983-8. doi: 10.1128/AAC.48.6.1983-1988.2004.
5
In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.克拉霉素和14-羟基克拉霉素与阿莫西林或次水杨酸铋对幽门螺杆菌的体外协同试验。
Antimicrob Agents Chemother. 1997 Jul;41(7):1607-8. doi: 10.1128/AAC.41.7.1607.
6
In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.奥美拉唑联合多种抗菌药物对幽门螺杆菌临床分离株的体外活性
Eur J Clin Microbiol Infect Dis. 1996 Dec;15(12):937-40. doi: 10.1007/BF01690512.
7
Use of time-kill methodology to assess antimicrobial combinations against metronidazole-susceptible and metronidazole-resistant strains of Helicobacter pylori.使用时间杀菌方法评估抗微生物组合对甲硝唑敏感和耐药幽门螺杆菌菌株的效果。
Antimicrob Agents Chemother. 1995 Dec;39(12):2641-4. doi: 10.1128/AAC.39.12.2641.
8
Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.胃质子泵抑制剂兰索拉唑对幽门螺杆菌脲酶活性具有强效抑制作用：对幽门螺杆菌细胞具有独特的选择性作用。
Antimicrob Agents Chemother. 1993 Apr;37(4):769-74. doi: 10.1128/AAC.37.4.769.
9
Evaluation of a rapid urease test to detect Campylobacter pylori infection.评估一种用于检测幽门螺杆菌感染的快速尿素酶试验。
J Clin Microbiol. 1988 Jul;26(7):1393-4. doi: 10.1128/jcm.26.7.1393-1394.1988.
10
Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents.幽门螺杆菌临床分离株对21种抗菌药物的敏感性
Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):566-9. doi: 10.1007/BF01962617.
本文引用的文献
1
[The Campylobacter pyloridis story].
Ned Tijdschr Geneeskd. 1986 Mar 8;130(10):435-6.
2
Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents.幽门弯曲菌对20种抗菌剂的敏感性
Antimicrob Agents Chemother. 1986 Sep;30(3):510-1. doi: 10.1128/AAC.30.3.510.
3
The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.抗生素和抗溃疡药物对幽门弯曲菌的最低抑菌浓度和杀菌浓度。
J Antimicrob Chemother. 1986 Mar;17(3):309-14. doi: 10.1093/jac/17.3.309.
4
Reversed incomplete cross-resistance among the older and newer quinolone antibiotics.
J Antimicrob Chemother. 1987 Mar;19(3):404. doi: 10.1093/jac/19.3.404.
5
Campylobacter pyloridis and gastritis.幽门弯曲菌与胃炎
J Infect Dis. 1986 Apr;153(4):650-7. doi: 10.1093/infdis/153.4.650.
6
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.幽门弯曲菌与相关胃炎：铋水杨酸酯和琥乙红霉素的研究者盲法、安慰剂对照试验
Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):645-9. doi: 10.1136/bmj.293.6548.645.
7
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.幽门弯曲菌临床分离株对11种抗菌药物的敏感性
Antimicrob Agents Chemother. 1985 Dec;28(6):837-8. doi: 10.1128/AAC.28.6.837.
8
[Nitrofurans: mode of action (author's transl)].
Ann Pharm Fr. 1979;37(9-10):421-8.
Zotero 插件